Hyperfine Posts 83% Revenue Growth on Portable MRI Expansion

Event summary

  • Q1 2026 revenue hit $3.9M, up 83% YoY, with 10 Swoop® systems sold
  • Secured CE Mark and UKCA approval for next-gen Swoop® system and Optive AI™ software
  • $15M debt financing extends cash runway into 2028
  • Contrast PMR study enrollment at 50% of target
  • Gross margin improved to 51% from 41% YoY

The big picture

Hyperfine's strong Q1 results reflect growing acceptance of portable MRI systems in both hospital and office settings. The company's ability to secure international regulatory clearances while maintaining 80%+ revenue growth suggests portable brain imaging is becoming a mainstream diagnostic tool. The $15M debt financing provides critical runway as Hyperfine expands into emerging markets like India.

What we're watching

Regulatory Momentum
Whether international approvals accelerate adoption beyond U.S. markets
Clinical Validation
How Contrast PMR study results impact FDA expansion plans
Operational Efficiency
The pace at which Hyperfine reduces cash burn while scaling